Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 4/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.34 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599049 | 0.82 | KDM5A (0.46) | HPGDKDM5APHF8KDM2AKDM4C | |
| SCHEMBL3588549 | 0.79 | KDM5A (0.47) | NAAAKDM5APHF8KDM2AKDM4C | |
| SCHEMBL3597712 | 0.78 | KDM5A (0.40) | KDM5APHF8KDM2AKDM4CKDM7A | |
| SCHEMBL3338716 | 0.77 | SIGMAR1 (0.50) | HPGDNAAAKDM5APHF8KDM2A | |
| SCHEMBL3591158 | 0.75 | KDM5A (0.40) | KDM5APHF8KDM2AKDM4CKDM7A | |
| SCHEMBL3590448 | 0.73 | LMNA (0.41) | POLBHPGDMEN1HTTKMT2A | |
| SCHEMBL3585506 | 0.72 | LMNA (0.37) | POLBHPGDMEN1HTTKMT2A | |
| SCHEMBL10323234 | 0.72 | KDM5A (0.40) | HPGDKDM5APHF8KDM2AKDM4C | |
| SCHEMBL4170832 | 0.72 | S1PR5 (0.43) | POLBHPGDNAAAKDM5APHF8 | |
| SCHEMBL14321921 | 0.72 | POLB (0.39) | POLBHPGDNAAAKDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | POLB 3415/4885HPGD 694/4885NAAA 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.